Switching from Semaglutide to Tirzepatide: What the Labels Say

There is no FDA-approved dose conversion from semaglutide to tirzepatide. A dose such as 1 mg of Ozempic or 2.4 mg of Wegovy does not translate into a particular Mounjaro or Zepbound dose. Current tirzepatide labels give their own starting and escalation schedules, while the exact stop date for semaglutide and first tirzepatide dose remain decisions for your prescriber. This guide was revised in September 2026 against the current U.S. labels.

Why there is no equivalent dose

Semaglutide activates the GLP-1 receptor. Tirzepatide activates both GIP and GLP-1 receptors. The products also have different approved uses and dose schedules, so milligrams cannot be compared as if they were the same drug. Even semaglutide tablets are not all interchangeable milligram for milligram; the current Rybelsus and Ozempic tablet label includes its own brand-specific conversion instructions.^[3]

The tirzepatide labels do not include a chart for converting from Ozempic, Wegovy, Rybelsus, or another semaglutide product. They instead start with tirzepatide's labeled initiation dose. That is why a history of tolerating a high semaglutide dose does not, by itself, establish that a high tirzepatide dose is appropriate.

What the current tirzepatide labels say

Mounjaro is labeled for type 2 diabetes, while Zepbound is labeled for chronic weight management and certain obesity-related conditions. Their current starting language is not identical, so the prescription should match the product and indication you are actually using.^[4][5] For a broader comparison of expected benefits and uses, see semaglutide vs tirzepatide.

How long should you wait between them?

The FDA labels do not give one cross-drug waiting period. Semaglutide has an elimination half-life of about one week and remains in circulation for roughly five weeks after the last Ozempic injection or semaglutide tablet dose, and about five to seven weeks after high-dose Wegovy.^[1][2][3] Tirzepatide's half-life is about five days.^[4]

Those long half-lives explain why your clinician considers the last dose date, current symptoms, glucose control, and other medicines. They do not mean everyone needs a five-week washout, and they do not create permission to start tirzepatide on the next weekly date without instructions. Someone switching from daily oral semaglutide also has no automatic weekly handoff day. Get a written stop date and first-dose date from the prescriber.

Information your prescriber needs

• Exact product and route: injection or tablet, and the brand name on the package.
• Dose and timing: your current dose, how long you have taken it, and the date and time of the last dose.
• Reason for switching: glucose control, weight response, availability, cost, side effects, or another clinical reason.
• Current symptoms: especially persistent nausea, vomiting, diarrhea, constipation, abdominal pain, or trouble keeping fluids down.
• Other medicines: particularly insulin or a sulfonylurea, because tirzepatide can increase hypoglycemia risk when combined with them.
• Relevant history: pancreatitis, gallbladder disease, severe gastroparesis, kidney problems, diabetic retinopathy, serious drug allergy, MTC, or MEN 2.
• Pregnancy and contraception: whether you are pregnant, planning pregnancy, or use an oral hormonal contraceptive.
• Planned procedures: tell the team before anesthesia or deep sedation because both drug families delay stomach emptying.

What to monitor after the first tirzepatide dose

Keep a simple daily record of the dose, injection site, nausea, vomiting, bowel changes, abdominal pain, food and fluid intake, and anything that stops normal activity. If you have diabetes, follow your clinician's glucose-check plan. People also taking insulin or a sulfonylurea may need closer checks and a medication adjustment; do not reduce those medicines on your own.^[4][5]

Nausea, diarrhea, vomiting, constipation, and abdominal discomfort are common with both drug families. A slow labeled escalation is intended to reduce gastrointestinal reactions, but it cannot predict who will tolerate one drug better. If symptoms are still significant when the next dose is due, contact the prescriber before taking it. JellyPal's Mounjaro tracker and Zepbound tracker can keep the dates and symptoms together for that conversation.

Safety checks that matter during a switch

• Do not combine the drugs on your own. Zepbound labeling says coadministration with another tirzepatide-containing product or any GLP-1 receptor agonist is not recommended.^[5]
• MTC or MEN 2: tirzepatide is contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The boxed warning is based on rat tumors; whether tirzepatide causes these tumors in humans is unknown. Read the GLP-1 boxed-warning guide.
• Pregnancy: weight loss is not recommended during pregnancy, and Zepbound should be stopped when pregnancy is recognized. Semaglutide labels advise stopping at least two months before a planned pregnancy; that two-month instruction is a pregnancy washout, not a routine switch interval.^[1][2][5]
• Oral hormonal contraception: tirzepatide may reduce its effectiveness. The labels advise a non-oral method or an added barrier method for four weeks after starting and for four weeks after every dose increase.^[4][5]
• Severe gastroparesis: Mounjaro and Zepbound are not recommended for people with severe gastroparesis. Tell the prescriber about ongoing fullness, vomiting, or suspected delayed stomach emptying before switching.

When to get help

Contact your prescriber promptly for severe or persistent gastrointestinal symptoms, repeated vomiting or diarrhea, inability to keep fluids down, signs of dehydration, new vision changes, or upper-abdominal pain with fever, jaundice, or clay-colored stools. The labels warn that fluid loss can contribute to acute kidney injury and that gallbladder disease can occur.^[4][5]

Stop the medicine and seek urgent medical care for severe abdominal pain that will not go away, especially if it reaches the back, because that can be a sign of pancreatitis. Get emergency help for trouble breathing, swelling of the face, lips, tongue, or throat, fainting, or other signs of a severe allergic reaction. Follow your established emergency plan for severe low blood sugar.

Frequently asked questions

Can I switch from 1 mg Ozempic directly to 5 mg Mounjaro?

The labels provide no equivalent-dose conversion. Current Mounjaro labeling names 2.5 mg once weekly as its starting dose, regardless of the semaglutide dose listed in your history. Your prescriber must choose the actual prescription and start date.

Do I have to wait one week?

There is no universal FDA-labeled one-week switch rule. Do not infer the first tirzepatide date from your old injection day; use the written plan from your prescriber.

Can semaglutide and tirzepatide be taken together?

Do not combine them on your own. Zepbound's label says coadministration with any GLP-1 receptor agonist is not recommended.^[5]

Will tirzepatide be easier on my stomach?

That cannot be predicted from the drug's dual-receptor action. Both drugs commonly cause gastrointestinal side effects, particularly during initiation and escalation. Your prior symptoms are useful planning information, not proof that the next drug will be easier or harder to tolerate. See the detailed tirzepatide side-effects guide.

References

1. FDA. Ozempic (semaglutide) injection - Prescribing Information, revised June 2026. DailyMed.
2. FDA. Wegovy (semaglutide) injection and tablets - Prescribing Information, revised June 2026. DailyMed.
3. FDA. Rybelsus and Ozempic (semaglutide) tablets - Prescribing Information, revised January 2026. DailyMed.
4. FDA. Mounjaro (tirzepatide) - Prescribing Information, revised August 2026. DailyMed.
5. FDA. Zepbound (tirzepatide) - Prescribing Information, revised August 2026. DailyMed.

Medical disclaimer: This article is general education, not a personal dosing plan. Do not stop, start, overlap, or change the dose of a prescription medicine without the clinician who manages it. Product labeling can change; the sources above were checked September 10, 2026.